Individual variation in factors affecting the steps between dose application and effects of antineoplastic agents

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 12, 2005, Pages 573-574

  Fuhr, Uwe ^a   Kirchheiner, J ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chemosensitivity; Genotype; Individualization; Metabolism; Microdialysis; Phenotype; Variability

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; MERCAPTOPURINE; PREDNISONE; PROCARBAZINE; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TRANSFORMATION; HOST; HUMAN; MAXIMUM TOLERATED DOSE; PHARMACOGENETICS; PLASMA PROTEIN BINDING; RISK BENEFIT ANALYSIS; SIDE EFFECT;

EID: 29444438472     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43573     Document Type: Article

References (7)

1. Ballova V, Ruffer JU, Haverkamp H, Pfistner B, Muller-Hermelink HK, Duhmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Loffler M, Diehl V, Engert A 2005 A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16: 124-131
2. Hunz M, Jetter A, Wilde S, König E, Warm M, Kurbacher C, Fuhr U 2001 Plasma and tissue pharmacokinetics of epirubicin in nine patients with primary breast cancer. Eur J Clin Pharmacol 57: A31
3. Kirchheiner J, Fuhr U, Brockmöller J 2005 Pharmacogenetics based therapeutic recommendations - ready to go into clinical practice? Nature Reviews Drug Discovery 4: 639-648
4. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A 2004 Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96: 1585-1592
5. Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, Kurbacher CM, Cree IA 2003 Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3: 19
6. Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M, Welte K, Ludwig WD, Bartram CR, Zanger UM, Eichelbaum M, Schrappe M, Schwab M 2005 Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293: 1485-1489
7. Wilde S, Jetter A, Rietbrock S, Kasel D, Sieber M, Tesch H, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Diehl V, Fuhr U 2004 Individual pharmacokinetics explain a major fraction of toxicity of BEACOPP therapy in Hodgkin's disease. Int J Clin Pharmacol Ther 42: 630